Infection by Enterohemorrhagic Escherichia coli (ICD-11: 1A03.3)

1. Introduction

Infection by enterohemorrhagic Escherichia coli (EHEC) represents one of the most severe forms of bacterial gastroenteritis, with potential for significant systemic complications. This condition is caused by specific strains of E. coli that produce powerful toxins known as verotoxins or Shiga-like toxins, named thus due to their structural and functional similarity to toxins produced by Shigella dysenteriae.

The most well-known and clinically relevant serotype is E. coli O157:H7, although other non-O157 serotypes can also cause severe disease. The distinctive characteristic of this infection is its ability to progress from initially moderate gastrointestinal symptoms to potentially fatal manifestations, including hemorrhagic colitis and hemolytic-uremic syndrome (HUS).

The clinical importance of this condition transcends mere gastroenteritis. EHEC is responsible for foodborne outbreaks that can affect hundreds of people simultaneously, generally associated with consumption of undercooked meat, contaminated vegetables, or untreated water. Mortality, although relatively low in healthy adults, increases significantly in vulnerable populations, particularly young children and the elderly.

Precise coding of this condition in ICD-11 under code 1A03.3 is essential for epidemiological surveillance, outbreak tracking, public health resource planning, and clinical research. Appropriate distinction among the different pathotypes of E. coli allows for targeted interventions and appropriate monitoring of specific complications associated with EHEC.

2. Correct ICD-11 Code

Code: 1A03.3

Description: Infection by enterohemorrhagic Escherichia coli

Parent category: 1A03 - Intestinal infections by Escherichia coli

Official definition: Infection by Escherichia coli caused by strains of enterohemorrhagic E. coli (EHEC) that produce toxins, known as verotoxins or Shiga-like toxins, due to their similarity to toxins produced by Shigella dysenteriae. Symptoms of diseases caused by EHEC include abdominal cramps and diarrhea that may, in some cases, progress to bloody diarrhea (hemorrhagic colitis). Fever and vomiting may also occur.

This code is part of the hierarchical structure of ICD-11 that organizes intestinal infections by E. coli according to their specific pathogenic mechanisms. The classification 1A03.3 allows precise identification of cases involving Shiga toxin production, differentiating them from other E. coli pathotypes that cause disease through distinct mechanisms such as adhesion, invasion, or enterotoxin production.

The correct application of this code facilitates recognition of epidemiological patterns, early identification of outbreaks, and implementation of appropriate infection control measures. It also enables health systems to monitor antimicrobial resistance trends and evaluate the effectiveness of preventive interventions.

3. When to Use This Code

Code 1A03.3 should be used in specific clinical situations where there is confirmation or strong suspicion of infection by Shiga toxin-producing E. coli. Below are detailed practical scenarios:

Scenario 1: Bloody diarrhea with laboratory confirmation Patient presents with initially watery diarrhea that progresses to frankly bloody stools after 2-3 days, accompanied by intense abdominal cramping. Stool culture or PCR testing confirms the presence of E. coli O157:H7 or another Shiga toxin-producing serotype. Fever is absent or low-grade, a characteristic that helps differentiate from other invasive bacterial infections.

Scenario 2: Hemorrhagic colitis documented by colonoscopy Patient with persistent bloody diarrhea who undergoes colonoscopy revealing significant colonic inflammation with areas of mucosal hemorrhage. Biopsy or stool culture identifies enterohemorrhagic E. coli. This scenario is common when the initial diagnosis is uncertain and endoscopic investigation is necessary to exclude other causes of colitis.

Scenario 3: Foodborne outbreak with multiple related cases Group of people who consumed a common food item (undercooked hamburger, raw vegetables) develops similar gastrointestinal symptoms. Epidemiological investigation identifies Shiga toxin-producing E. coli in the food source and in samples from affected patients. All confirmed cases should receive code 1A03.3, even those with milder symptoms.

Scenario 4: Hemolytic-uremic syndrome preceded by gastroenteritis Child who presented with bloody diarrhea 5-10 days prior develops signs of hemolytic-uremic syndrome (hemolytic anemia, thrombocytopenia, acute renal failure). Serological or stool testing confirms recent EHEC infection. In this case, both code 1A03.3 and codes for HUS should be used.

Scenario 5: Detection of Shiga toxin in stool without bacterial isolation Patient with compatible clinical presentation (bloody diarrhea, abdominal cramping) whose stool test detects Shiga toxin genes (stx1 or stx2) by molecular methods, even without bacterial isolation in culture. Molecular detection of toxins is sufficient to justify code 1A03.3.

Scenario 6: Confirmed infection with atypical manifestation Elderly or immunocompromised patient with documented EHEC infection who presents with less typical gastrointestinal symptoms, such as diarrhea without visible blood, but with laboratory evidence of occult blood in stool and microbiological confirmation of Shiga toxin-producing E. coli.

4. When NOT to Use This Code

It is essential to distinguish situations where code 1A03.3 is not appropriate, even in the presence of E. coli infection:

Infections by other E. coli pathotypes: When culture or molecular tests identify enteropathogenic E. coli (EPEC), enterotoxigenic (ETEC), enteroinvasive (EIEC), or enteroaggregative (EAEC), specific codes within category 1A03 should be used. The absence of genes for Shiga toxin or verotoxin excludes the diagnosis of EHEC.

Bloody diarrhea from other etiologies: Colitis caused by Shigella, Campylobacter, Salmonella, or Clostridium difficile may present with similar clinical presentation. Differentiation requires specific laboratory confirmation. EHEC should not be presumed based solely on the presence of blood in stool without confirmatory tests.

Inflammatory bowel disease: Crohn's disease or ulcerative colitis may manifest with bloody diarrhea and abdominal cramping. Clinical history, characteristic endoscopic findings, and absence of identified pathogen direct toward codes for inflammatory bowel diseases.

Asymptomatic colonization: Individuals who shed Shiga toxin-producing E. coli in stool without clinical symptoms should not receive code 1A03.3. Asymptomatic carriers identified during contact tracing in outbreaks require different documentation.

Unspecified E. coli infection: When there is confirmation of E. coli in stool culture but without characterization of the pathotype or detection of virulence factors, more general codes should be used until additional tests clarify the nature of the strain.

5. Step-by-Step Coding Process

Step 1: Assess diagnostic criteria

Diagnostic confirmation of EHEC infection requires a combination of clinical manifestations and laboratory confirmation. Clinically, seek the characteristic triad: diarrhea that progresses to bloody, intense abdominal cramps, and absent or low-grade fever (usually below 38.5°C). Epidemiological history is crucial: investigate consumption of high-risk foods in the last 72 hours to 10 days.

Laboratorially, diagnosis can be established through: fecal culture on selective media (MacConkey-sorbitol agar for O157:H7), immunological tests for Shiga toxin detection, PCR for stx1 and stx2 genes, or serotyping of E. coli isolates. Modern molecular tests allow rapid detection even when culture is negative.

Complementary evaluations include complete blood count (to detect anemia, leukocytosis, or thrombocytopenia), renal function (urea and creatinine), electrolytes, and urinalysis. These tests are essential to identify early complications, particularly hemolytic-uremic syndrome.

Step 2: Verify specifiers

Although code 1A03.3 does not have formal subdivisions in ICD-11, clinical documentation should specify: identified serotype (O157:H7 or non-O157), severity of presentation (simple diarrhea versus hemorrhagic colitis), presence of complications (HUS, thrombotic thrombocytopenic purpura), and epidemiological context (sporadic case versus outbreak-related).

Duration of symptoms should also be recorded, as most cases resolve in 5-10 days, but complications may arise after apparent resolution of diarrhea. Documenting temporal evolution aids in pattern recognition and identification of high-risk cases.

Step 3: Differentiate from other codes

1A03.0 - Infection by enteropathogenic Escherichia coli (EPEC): Causes watery diarrhea without blood, mainly in infants. Pathogenic mechanism involves adhesion to intestinal mucosa without Shiga toxin production. Fever may be present. Laboratory tests do not detect stx genes.

1A03.1 - Infection by enterotoxigenic Escherichia coli (ETEC): Leading cause of traveler's diarrhea. Produces heat-labile or heat-stable enterotoxins, not Shiga toxins. Presents with profuse watery diarrhea without blood, cramps, and occasionally vomiting. Rarely causes fever or systemic complications.

1A03.2 - Infection by enteroinvasive Escherichia coli (EIEC): Causes dysentery similar to shigellosis, with high fever, bloody diarrhea, and prominent systemic symptoms. Mechanism involves invasion of epithelial cells, not toxin production. High fever helps differentiate from EHEC.

Definitive differentiation requires specific laboratory tests that identify virulence factors characteristic of each pathotype.

Step 4: Required documentation

Adequate documentation should include:

Mandatory checklist:

Detailed description of gastrointestinal symptoms (frequency, consistency, presence of blood)
Precise chronology of symptom onset and evolution
Dietary and epidemiological history from the last two weeks
Fecal culture results or molecular tests confirming EHEC
Serotype identification when available
Results of Shiga toxin tests (immunological or molecular)
Evaluation of complications (renal function, blood count)
Therapeutic measures implemented
Guidance on contact precautions and public health notification

This complete documentation not only justifies the coding but also facilitates epidemiological investigations and contact tracing.

6. Complete Practical Example

Clinical Case:

A 42-year-old male patient, previously healthy, seeks medical care with a complaint of diarrhea for 4 days. He reports that initially he presented with liquid stools without blood, accompanied by moderate abdominal cramping. In the last 24 hours, he noticed the presence of bright red blood in his bowel movements, which became more frequent (8-10 episodes/day). The cramping intensified significantly, localized mainly in the periumbilical region and left iliac fossa.

On physical examination, the patient is dehydrated (dry mucous membranes, decreased skin turgor), axillary temperature measured at 37.8°C, abdomen tender to diffuse palpation without signs of peritoneal irritation, increased bowel sounds. There are no palpable masses or visceromegaly.

On directed history, the patient reports having participated in a family barbecue 6 days ago, where he consumed hamburgers that were "pink inside." Other family members who attended the event presented with mild gastrointestinal symptoms.

Laboratory tests were requested: complete blood count showed leukocytes 12,000/mm³ with left shift, hemoglobin 14.2 g/dL, platelets 180,000/mm³. Normal renal function (creatinine 0.9 mg/dL, urea 32 mg/dL). Electrolytes within normal limits.

Stool culture was collected and sent for analysis. Rapid immunochromatography test for Shiga toxin detection was positive. Subsequently, PCR confirmed the presence of stx2 and eae genes. Culture on MacConkey-sorbitol agar identified sorbitol non-fermenting colonies, later confirmed as E. coli O157:H7.

Step-by-Step Coding:

Criteria Analysis:

Clinical criteria met: Diarrhea progressing to bloody, intense abdominal cramping, low-grade/absent fever
Epidemiological criteria: Exposure to high-risk food (undercooked meat) during appropriate incubation period (3-8 days)
Laboratory criteria: Detection of Shiga toxin, molecular confirmation of stx genes, isolation of E. coli O157:H7

Code selected: 1A03.3 - Infection by enterohemorrhagic Escherichia coli

Complete justification:

Code 1A03.3 is appropriate because there is definitive confirmation of infection by Shiga toxin-producing E. coli through multiple methods (rapid test, PCR, culture). The clinical presentation is characteristic of EHEC: diarrhea progressing to bloody, intense cramping, absent/low-grade fever. The epidemiological history (consumption of undercooked meat) is consistent with typical transmission route.

Complementary codes:

E86 - Volume depletion (dehydration) - to document complication present
Z code for history of exposure to contaminated food, if available in the recording system

Follow-up plan: Patient was counseled on adequate hydration, avoidance of antidiarrheal and antibiotic use (which may increase HUS risk), to return immediately if developing decreased urine output, pallor, or petechiae. Laboratory monitoring of renal function and complete blood count scheduled for 48-72 hours. Notification to public health authorities was made for epidemiological investigation of the family event.

7. Related Codes and Differentiation

Within the Same Category:

1A03.0 - Infection by enteropathogenic Escherichia coli

When to use vs. 1A03.3: Use 1A03.0 when there is confirmation of typical or atypical EPEC, characterized by localized adhesion pattern to intestinal mucosa. The typical clinical presentation is persistent watery diarrhea in infants and young children, without progression to bloody diarrhea.

Main difference: EPEC does not produce Shiga toxins. The pathogenic mechanism involves attaching and effacing lesions mediated by the LEE pathogenicity island, without the severe systemic consequences associated with Shiga toxins. Molecular tests detect eae gene but not stx genes.

1A03.1 - Infection by enterotoxigenic Escherichia coli

When to use vs. 1A03.3: Apply 1A03.1 when enterotoxigenic ETEC producing heat-labile (LT) or heat-stable (ST) enterotoxins is identified. Clinically manifests as profuse watery diarrhea, frequently in the context of travel to endemic areas or consumption of contaminated water/food.

Main difference: ETEC causes secretory diarrhea through enterotoxins that alter electrolyte transport, not through cytotoxicity. There is no progression to bloody diarrhea or systemic complications such as HUS. The diarrhea is watery, non-inflammatory, and self-limited (3-5 days).

1A03.2 - Infection by enteroinvasive Escherichia coli

When to use vs. 1A03.3: Use 1A03.2 when EIEC is identified, causing dysentery-like syndrome with invasion of colonic epithelial cells. Clinical presentation includes high fever, bloody diarrhea with mucus, tenesmus, and prominent systemic symptoms.

Main difference: EIEC invades intestinal cells similar to Shigella, causing intense colonic inflammation with high fever. Significant fever (usually above 38.5°C) contrasts with the low/absent fever typical of EHEC. Does not produce Shiga toxins and rarely causes renal complications.

Differential Diagnoses:

Shigellosis: Can be confused with EHEC due to bloody diarrhea, but generally presents with high fever, intense tenesmus, and more pronounced systemic symptoms. Culture differentiates Shigella from E. coli.

Campylobacter colitis: Causes bloody diarrhea with fever, but culture on specific media and microscopy (curved motile bacilli) allow differentiation.

Pseudomembranous colitis (C. difficile): Generally occurs after antibiotic use, with detection of C. difficile toxins in stool. Colonoscopy may show characteristic pseudomembranes.

Inflammatory bowel disease: Chronic or recurrent history, characteristic endoscopic findings (deep ulcers, involvement pattern), and specific histopathology differentiate from acute infection.

8. Differences with ICD-10

In ICD-10, infection by enterohemorrhagic E. coli was coded as A04.3 - Infection by enterohemorrhagic Escherichia coli. The transition to ICD-11 brought significant structural changes in the organization of intestinal infections by E. coli.

Main changes in ICD-11:

The hierarchical structure was reorganized, creating the parent category 1A03 specifically for intestinal infections by E. coli, with clearer subdivisions based on pathotypes. In ICD-10, there was less specificity in differentiating between the different pathogenic mechanisms of diarrheagenic E. coli.

ICD-11 adopts nomenclature more aligned with current scientific literature, emphasizing Shiga toxin production as a defining characteristic. The expanded definition in ICD-11 explicitly mentions verotoxins and the relationship with Shigella dysenteriae toxins, providing greater conceptual clarity.

Practical impact of these changes:

More specific coding in ICD-11 facilitates differentiated epidemiological surveillance among E. coli pathotypes, allowing more precise tracking of EHEC outbreaks versus other types of diarrheagenic E. coli. Health systems can now clearly distinguish cases of EHEC (with HUS risk) from ETEC (usually benign) in electronic records.

The transition requires updating computerized systems and training coders to correctly apply the new structure. Epidemiological studies comparing historical data (ICD-10) with current data (ICD-11) should consider these changes in classification to ensure adequate comparability.

9. Frequently Asked Questions

How is a definitive diagnosis of EHEC infection made?

Definitive diagnosis requires laboratory confirmation through stool culture on selective media, immunological tests for Shiga toxin detection, or molecular methods (PCR) that identify Shiga toxin genes (stx1 and stx2). Modern molecular methods offer greater sensitivity and speed, detecting bacterial DNA even when culture is negative. The combination of characteristic clinical presentation (bloody diarrhea, severe cramping, low-grade/absent fever) with positive laboratory tests establishes the diagnosis. Additional serotyping can identify specific strains such as O157:H7, but is not necessary for initial diagnosis.

Is treatment available in public health systems?

Management of EHEC infection is widely available in public health systems, although it is primarily supportive. Treatment consists of adequate hydration (oral or intravenous depending on severity), correction of electrolyte disturbances, and careful monitoring for early detection of complications. Antibiotics are generally contraindicated, as studies demonstrate that they may increase the risk of hemolytic-uremic syndrome by promoting toxin release. Complicated cases with HUS may require dialysis, transfusions, and intensive care, available at referral centers. Most uncomplicated cases can be managed on an outpatient basis with regular clinical follow-up.

How long does treatment and recovery last?

The duration of illness varies according to severity. Uncomplicated cases generally show symptom resolution in 5-10 days with supportive treatment. Bloody diarrhea typically improves after 4-7 days, although bacterial shedding in stool may persist for 2-3 weeks. Patients should be followed for at least 2-3 weeks after symptom onset to monitor for possible development of HUS, which can occur up to 10 days after diarrhea begins. Complicated cases with HUS require prolonged treatment, with recovery of renal function potentially taking weeks to months. Some patients may develop chronic renal sequelae requiring long-term follow-up.

Can this code be used in medical certificates and occupational documentation?

Yes, code 1A03.3 can and should be used in medical certificates, work absence declarations, and occupational documentation when appropriate. EHEC infection justifies absence from work, particularly for professionals who handle food, work in healthcare, or in childcare settings, due to transmission risk. The period of absence should consider symptom resolution and, in some situations, negative stool cultures before return to high-risk activities. Documentation should specify "bacterial intestinal infection" without necessarily detailing the specific pathogen, respecting patient privacy while providing adequate medical justification.

What are the transmission risks and how long does a person remain contagious?

Transmission occurs primarily via fecal-oral route, through contaminated food (undercooked meat, raw vegetables, unpasteurized milk), contaminated water, or person-to-person contact. The infectious dose is very low (10-100 organisms), facilitating transmission. Patients remain contagious while shedding the bacteria in stool, typically 1-3 weeks after symptom onset, although children may shed for longer periods. Rigorous hygiene precautions (hand washing, surface disinfection, proper handling of contaminated clothing and materials) are essential throughout the symptomatic period and until confirmation that bacterial shedding has ceased.

Do children and elderly individuals have a higher risk of complications?

Yes, children under 5 years of age and elderly individuals over 65 years present significantly increased risk of serious complications, particularly hemolytic-uremic syndrome. In young children, the risk of developing HUS after EHEC infection can reach 10-15% of cases, compared to less than 5% in healthy adults. Elderly individuals have greater risk of severe dehydration, cardiovascular complications, and mortality. These age groups require more intensive monitoring, including frequent laboratory assessments of renal function and complete blood count, even in apparently mild cases. Hospitalization should be considered more readily in these patients to ensure adequate hydration and early detection of complications.

Is it necessary to notify public health authorities?

Yes, EHEC infections are considered notifiable diseases in virtually all health systems due to epidemic potential and severity. Notification enables rapid epidemiological investigation, identification of common sources of infection, implementation of control and prevention measures, and prevention of secondary cases. Healthcare professionals must notify suspected and confirmed cases to local health authorities, providing information about food exposures and contacts. In outbreak situations, coordinated investigation can identify and remove contaminated food from the distribution chain, preventing new cases.

Is there a vaccine or specific preventive measures?

Currently there is no vaccine available for prevention of EHEC infection. Prevention is based on food safety measures: adequate cooking of meat (minimum internal temperature of 70°C), avoiding consumption of unpasteurized milk, carefully washing raw vegetables, preventing cross-contamination in food preparation, and ensuring adequate hand hygiene. In rural areas, avoiding contact with animal feces and untreated surface water is important. During outbreaks, follow guidance from health authorities regarding foods to avoid. Education on safe food handling practices is the most effective preventive strategy currently available.

Conclusion: Appropriate coding of enterohemorrhagic Escherichia coli infection using ICD-11 code 1A03.3 requires clear understanding of diagnostic criteria, differentiation from other E. coli pathotypes, and recognition of the distinctive clinical characteristics of this potentially serious condition. Correct application of this code facilitates epidemiological surveillance, appropriate clinical management, and prevention of serious complications such as hemolytic-uremic syndrome.

External References

This article was prepared based on reliable scientific sources:

References verified on 2026-02-04

Infection by Enterohemorrhagic Escherichia coli

Compartilhar